Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 122 of 122 entries
Sorted by: Best Match Show Resources per page
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.

Clinical pharmacology and therapeutics

Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S.
PMID: 34312836
Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23.

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug...

Cite
Hee Nam Y, Brensinger CM, Bilker WB, et al. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021;111(1):218-226doi: 10.1002/cpt.2377.
Hee Nam, Y., Brensinger, C. M., Bilker, W. B., Flory, J. H., Leonard, C. E., & Hennessy, S. (2022). Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical pharmacology and therapeutics, 111(1), 218-226. https://doi.org/10.1002/cpt.2377
Hee Nam, Young, et al. "Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia." Clinical pharmacology and therapeutics vol. 111,1 (2022): 218-226. doi: https://doi.org/10.1002/cpt.2377
Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23. PMID: 34312836; PMCID: PMC8678147.
Copy Download .nbib Format: NLM
Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes.

American journal of perinatology

Palatnik A, Harrison RK, Thakkar MY, Walker RJ, Egede LE.
PMID: 34758497
Am J Perinatol. 2021 Nov 10; doi: 10.1055/s-0041-1739266. Epub 2021 Nov 10.

OBJECTIVE:  The aim of this study was to investigate prenatal factors associated with insulin prescription as a first-line pharmacotherapy for gestational diabetes mellitus (GDM; compared with oral antidiabetic medication) after failed medical nutrition therapy.METHODS:  This is a retrospective cohort...

Cite
Palatnik A, Harrison RK, Thakkar MY, et al. Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes. Am J Perinatol. 2021;doi: 10.1055/s-0041-1739266.
Palatnik, A., Harrison, R. K., Thakkar, M. Y., Walker, R. J., & Egede, L. E. (2021). Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes. American journal of perinatology, . https://doi.org/10.1055/s-0041-1739266
Palatnik, Anna, et al. "Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes." American journal of perinatology vol. (2021). doi: https://doi.org/10.1055/s-0041-1739266
Palatnik A, Harrison RK, Thakkar MY, Walker RJ, Egede LE. Correlates of Insulin Selection as a First-Line Pharmacological Treatment for Gestational Diabetes. Am J Perinatol. 2021 Nov 10; doi: 10.1055/s-0041-1739266. Epub 2021 Nov 10. PMID: 34758497.
Copy Download .nbib Format: NLM
Showing 121 to 122 of 122 entries